53.60
+0.86(+1.63%)
Currency In USD
| Previous Close | 52.74 |
| Open | 52.28 |
| Day High | 54.25 |
| Day Low | 51.73 |
| 52-Week High | 62.53 |
| 52-Week Low | 33.67 |
| Volume | 1.61M |
| Average Volume | 735,803 |
| Market Cap | 4.97B |
| PE | -14.49 |
| EPS | -3.7 |
| Moving Average 50 Days | 56.91 |
| Moving Average 200 Days | 50.51 |
| Change | 0.86 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $2,186.86 as of December 21, 2024 at a share price of $53.6. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $2,362.27 as of December 21, 2024 at a share price of $53.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
GlobeNewswire Inc.
Dec 16, 2024 1:00 PM GMT
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company’s commercial strategy and operations fo
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 11, 2024 1:44 AM GMT
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an agg
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
GlobeNewswire Inc.
Dec 09, 2024 1:00 PM GMT
FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted it